Cabaletta Bio, Inc. Common Stock
CABAStock
$2.67+57.99%52W
Market Cap$446.77M
P/E—
Div yield—
Beta3.26
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)22.21%
Price vs S&P 500 (4W)-10.90%
VGM Score48.90
Market Capitalization$446.77M
Earnings Surprise History
Q1 26-0.39est. -0.41
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.19
4.19
4.19
4.19
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CABACabaletta Bio, Inc. Common Stock | — | — | C | $2.67 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary CAART technology selectively eliminates disease-causing B cells while preserving normal B cells, offering the potential for deep and durable therapeutic effects. The company's CABA platform encompasses multiple strategies applicable across a broad range of autoimmune indications.